EUCTR2008-002204-25-FR进行中（未招募）1 期
A Phase 2, Randomized, Open-Label Study to Evaluate ECG Results and Pharmacokinetic Parameters for Fludarabine, Cyclophosphamide, and Rituximab (FCR) in Combination with Lumiliximab Versus FCR Alone in Subjects with Previously Untreated Chronic Lymphocytic Leukemia.
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Ability to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use protected health information (PHI) in accordance with national and local subject privacy regulations.
- •2.Age =18 years at the time of informed consent.
- •3.Previously untreated CD23+ and CD20+ B cell CLL as defined by NCI WG Guidelines (1996).
- •4.Life expectancy >6 months in the opinion of the Investigator.
- •5.Subjects with Rai Stage III or IV (Binet Stage C), or Rai Stage I or II (Binet Stage A or B) if determined to have disease progression as evidenced by rapid doubling of peripheral lymphocyte count, progressive lymphadenopathy, progressive splenomegaly, or B symptoms (Staging Criteria – Modified Rai).
- •6.World Health Organization (WHO) Performance Status=2.
- •7.Normal ECG with QTc =450 msec for men and =460 msec for women. PR interval (Print) must be <240 msec and QRS complex <110 msec. T wave flattening and T wave inversion will be permitted.
- •8.All male subjects and female subjects of childbearing potential must practice effective contraception during the study and be willing and able to continue contraception for 12 months after their last dose of study treatment. For further details of contraceptive requirements for this study, please refer to Section 15.5.3.
- •9.Acceptable liver function at Screening:
- •Bilirubin=2.0 mg/dL (34.2 µmol/L).
- •Alanine aminotransferase (ALT) and aspartate aminotransferase (AST)=2 times the upper limit of normal.
- •10.Acceptable hematologic status at Screening:
- •Platelet count =50 x10 9 /L not supported by transfusion.
- •Absolute neutrophil count (ANC) =1 x 10 9/L.
- •11.Acceptable renal function at Screening:
- •Creatinine clearance calculated according to the formula of Cockroft and Gault > 50 mL/min.
- •Serum creatinine =1.5 times the upper limit of normal.
- •12.Subjects receiving any medication known to affect the QTc interval must discontinue the use of medication or be on a stable dose of medication for at least 3 months or 5 half lives (whichever is longer) prior to Study Day 1, and continue (whenever possible) at the same dose throughout the study.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Any prior therapy for CLL, including radiotherapy, radioimmunotherapy, biological therapy, chemotherapy, allogeneic/autologous bone marrow transplant, peripheral blood stem cell transplant, or other investigational therapy.
- •2.Known history of or positive test result for human immunodeficiency virus.
- •3.Known history of, or positive test result for Hepatitis C virus (test for Hepatitis C virus antibody) or Heptatitis B virus (test for Hepatitis B Surface Antigen and Hepatitis B Core Antibody) at Screening.
- •4.Uncontrolled diabetes mellitus.
- •5.Uncontrolled hypertension.
- •6.Hypokalemia, as defined by potassium below the lower limit of normal on the central laboratory results at Screening.
- •7.New York Heart Association Class III or IV cardiac disease; myocardial infarction within the past 6 months prior to Study Day 1.
- •8.Arrhythmia (other than sinus arrhythmia) within 30 days prior to Study Day 1.
- •9.Evidence of active myocardial ischemia on ECG (new T wave changes with chest pain or presence of elevation of cardiac enzymes) within 30 days prior to
- •Study Day 1.
- •10.Subjects with pacemakers.
- •11.Transformation to aggressive B-cell malignancy (e.g., large B cell lymphoma, Richter’s Syndrome, or prolymphocyte leukemia [PLL]).
- •12.Secondary malignancy requiring active treatment.
- •13.Any medical condition that would require long-term use (?1 month) of systemic corticosteroids during study treatment, and use of systemic corticosteroids for treatment of CLL during the study for any time period.
- •14.Any serious nonmalignant disease or laboratory abnormality, which would confound the evaluation of AEs.
- •15.Active bacterial, viral, or fungal infections.
- •16.Any known family history of long QT syndrome.
- •17.Seizure disorders requiring anticonvulsant therapy.
- •18.Severe chronic obstructive pulmonary disease with hypoxemia.
- •19.Major surgery, other than diagnostic surgery, within 4 weeks prior to Study Day 1.
- •20.Clinically active autoimmune disease.
- •21.Coombs-positive hemolytic anemia.
- •22.Pregnant or currently breastfeeding at Screening.
- •23.Prior exposure to lumiliximab or other anti-CD23 antibody.
研究者
相似试验
招募中
2 期
A Phase 2, Randomized, Open-Label Study to Evaluate theSafety and Efficacy of GS-4774 for the Treatment ofVirally-Suppressed Subjects with Chronic Hepatitis BACTRN12613001080718Gilead Sciences, Inc175
进行中（未招募）
1 期
A study looking at the safety and effectiveness of treatment with GS-4774 in combination with Tenofovir Disoproxil Fumarate (TDF) for patients with chronic Hepatitis B infection who are not already receiving treatment for their infectioChronic Hepatitis BMedDRA version: 17.1Level: PTClassification code 10008910Term: Chronic hepatitis BSystem Organ Class: 10021881 - Infections and infestationsEUCTR2014-001011-39-ITGilead Sciences, Inc.175
进行中（未招募）
不适用
A Phase 2, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Fludarabine, Cyclophosphamide, and Rituximab (FCR) in Combination with Lumiliximab Versus FCR Alone in Subjects with Previously Untreated Chronic Lymphocytic LeukemiaPreviously Untreated Chronic Lymphocytic Leukemia (CLL)MedDRA version: 9.1Level: LLTClassification code 10008958Term: Chronic lymphocytic leukaemiaEUCTR2008-002204-25-BEBiogen Idec Ltd40
进行中（未招募）
不适用
A Phase 2, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Fludarabine,Cyclophosphamide, and Rituximab (FCR) in Combination with Lumiliximab Versus FCR Alone in Subjects with Previously Untreated Chronic Lymphocytic LeukemiaPreviously Untreated Chronic Lymphocytic Leukemia (CLL)MedDRA version: 9.1Level: LLTClassification code 10008958Term: Chronic lymphocytic leukaemiaEUCTR2008-002204-25-ATBiogen Idec Ltd40
进行中（未招募）
不适用
A Phase 2, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Fludarabine, Cyclophosphamide, and Rituximab (FCR) in Combination with Lumiliximab Versus FCR Alone in Subjects with Previously Untreated Chronic Lymphocytic Leukemia.Previously Untreated Chronic Lymphocytic Leukemia (CLL)MedDRA version: 9.1Level: LLTClassification code 10008958Term: Chronic lymphocytic leukaemiaEUCTR2008-002204-25-GBBiogen Idec Ltd40